Evolution of Hemophilia Care in India

  • Kanjaksha Ghosh
Original Article


Haemophilia is a high cost low volume disease. Being a relatively uncommon condition governments of the day are not very interested in developing comprehensive care for such a condition. Patient’s society where such kind of patients come together under one umbrella and fight for their rights and proper management of the condition has important role to play in developing and helping to deliver high standards care in such a condition. Haemophilia Federation of India, a patient’s organization played a stellar role in developing haemophilia care in this country and continues to do so today, present article explains how this organization engaged itself through local, national and international interaction in evolving haemophilia care in this country. The present description can act as a template for developing similar architecture of care for rare but difficult and costly to treat disorders’.


Haemophilia Haemophilia federation of India Government Gene therapy Recent advances in treatment 



Mr Vikas Goel, Dr. Devila Sahu, Wg.Cdr S. Roychoudhury and all my PWH friends of HFI.

Compliance with Ethical Standards

Conflict of interest

Author declares no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed Consent

Not applicable.


  1. 1.
    Chatterjea JB (1960) A brief review of the hematologic literature from India (1959). Blood 16:1351–1355PubMedGoogle Scholar
  2. 2.
    Mathur KS, Gupta OP (1957) Hemophilia syndrome with ulnar nerve palsy. J Indian Med Assoc 29:233–236PubMedGoogle Scholar
  3. 3.
    Chatterjea JB, Kundu HB (1961) Characteristic study of hemophilia syndrome. J Assoc Phys India 9:361–367Google Scholar
  4. 4.
    Banerji LB (1962) Haemophilic pseudotumour in a patient with AHG (factor VIII) deficiency. J Assoc Physicians India 10:749–753PubMedGoogle Scholar
  5. 5.
    Nanu A, Taneja N, Madan N, Sood SK (1980) Preparation and standardization of fresh frozen plasma and cryoprecipitate in a developing blood bank. Indian J Pathol Microbiol 23:235–240PubMedGoogle Scholar
  6. 6.
    De M, Banerjee D, Chandra S, Bhattacharya DK (1989) A simple method for preparation of good quality cryoprecipitate. Indian J Med Res 90:32–35PubMedGoogle Scholar
  7. 7.
    Ghosh K, Shetty S, Sahu D (2010) Haemophilia care in India: innovations and integrations by various chapters of Haemophilia Federation of India (HFI). Haemophilia 16:61–65CrossRefGoogle Scholar
  8. 8.
    Kanani P, Poudyal BS, Shetty S, Kapali SM, Ghosh K (2012) Heterozygote frequencies of common polymorphic markers of factor VIII (f8) and factor IX (f9) genes in indigenous Nepali population. Haemophilia 18(2):e44–e45CrossRefGoogle Scholar
  9. 9.
    Patil A, Poudyal BS, Kapali SM, Ghosh K, Shetty S (2013) Prevalence of factor V G1691A, factor II G20210A, methylenetetrahydrofolate reductase C677T and endothelial protein C receptor 23 bp insertion polymorphisms in indigenous population of Nepal. Ann Hematol 92(2):261–262CrossRefGoogle Scholar
  10. 10.
    Skinner MW (2012) WFH: closing the global gap-achieving optimal care. Haemophilia 18(Suppl 4):1–12CrossRefGoogle Scholar
  11. 11.
    Shetty S, Shelar T, Mirgal D, Nawadkar V, Pinto P, Shabhag S, Mukaddam A, Kulkarni B, Ghosh K (2014) Rare coagulation factor deficiencies: a countrywide screening data from India. Haemophilia 20:575–581CrossRefGoogle Scholar
  12. 12.
    Kulkarni BP, Nair SB, Vijapurkar M, Mota L, Shanbhag S, Ali S, Shetty SD, Ghosh K (2014) Molecular pathology of rare bleeding disorders (RBDs) in India: a systematic review. PLoS ONE 9(9):e108683. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Pinto P, Shelar T, Nawadkar V, Mirgal D, Mukaddam A, Nair P et al (2014) The Epidemiology of FVIII Inhibitors in Indian haemophilia A patients. Indian J Hematol Blood Transfus 30:356–363CrossRefGoogle Scholar
  14. 14.
    Peyvandi F, Garagiola I (2015) Treatment of hemophilia in the near future. Semin Thromb Hemost 41:838–848CrossRefGoogle Scholar
  15. 15.
    Pierce GF, Iorio A (2018) Past, present and future of haemophilia gene therapy: from vectors and transgenes to known and unknown outcomes. Haemophilia 24(Suppl 6):60–67CrossRefGoogle Scholar
  16. 16.
    Mahlangu J, Cerquiera M, Srivastava A (2018) Emerging therapies for haemophilia—global perspective. Haemophilia 24(Suppl 6):15–21CrossRefGoogle Scholar
  17. 17.
    Janbain M, Pipe S (2016) What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors? Hematol Am Soc Hematol Educ Program 2016:648–649CrossRefGoogle Scholar
  18. 18.
    Parvathaneni K, Abdeladhim M, Pratt KP, Scott DW (2017) Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy. Transl Res 187:44–52CrossRefGoogle Scholar
  19. 19.
    Ghosh K, Shukla R (2017) Future of haemophilia research in India. Indian J Hematol Blood Transfus 33:451–452CrossRefGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  1. 1.Surat Raktadan Kendra & Research CentreSuratIndia

Personalised recommendations